Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics

Zheng, Lirong; Hu, Jianguo; Chen, Chih Ken; Lan, Tsuo Hung; Diokno, Gregorio L.; Lee, Byoung Yong; McElroy, Heather; Harrison, Gavan; Ang, Qiuqing

doi:10.1016/j.pnpbp.2006.06.006

Cited by 12 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This similar study found significant improvements in symptoms of schizophrenia, health-related quality of life, and involuntary movements, and a greater weight gain. 30 The findings from the current study, which specifically documents the naturalistic outcomes of patients with schizophrenia in the Japanese health care system who were switched from typical antipsychotics to olanzapine are consistent with the findings from studies in other geographic regions.…”

Section: Discussionsupporting

confidence: 85%

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study

Ye¹,

Fujikoshi²,

Nakahara³

et al. 2012

POR

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to assess the 1-year clinical, functional, and safety-related outcomes following a switch to olanzapine of at least one typical antipsychotic drug in the previous regimen in the treatment of patients of schizophrenia in Japan.MethodsUsing data from a large 1-year prospective, multicenter, naturalistic study of olanzapine for the treatment of schizophrenia in Japan, patients who were switched from any oral typical antipsychotic to olanzapine were identified. Mixed models for repeated measures, controlling for baseline demographics, were utilized to assess outcomes for clinical and functional measures.ResultsOf the 262 patients who switched from typical antipsychotics to olanzapine, 41% were outpatients and 59% were inpatients. Most of these patients were switched due to poor medication efficacy (71.0%) or medication intolerability (25.6%). Most patients (71.4%) completed the 1-year study. Clinically and statistically significant (P < 0.01) improvements were observed in patient illness severity and health-related quality of life, including improvements in global symptom severity and in positive, negative, depressive, and cognitive symptoms. Over half of the patients (58.3%) demonstrated a treatment response to olanzapine and 47.4% achieved symptom remission. Mean weight gain from baseline to endpoint was 2.31 ± 4.72 kg, with 30.4% of patients experiencing clinically significant weight gain (at least 7% of baseline weight).ConclusionDuring this 1-year naturalistic treatment of schizophrenia patients in Japan, switching from typical antipsychotics to olanzapine resulted in significant improvements in patients’ clinical and functional outcomes. Approximately one-third of patients had clinically significant weight gain. These findings highlight the favorable benefit to risk profile of switching to olanzapine following failure on typical antipsychotics.

show abstract

Section: Discussionsupporting

confidence: 85%

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study

Ye¹,

Fujikoshi²,

Nakahara³

et al. 2012

POR

View full text Add to dashboard Cite

show abstract

“…In the parent study, a total of 1,272 Asian subjects with schizophrenia were enrolled, of whom five did not meet eligibility criteria. 15 Of the remaining 1,267 patients, 475 were from the People’s Republic of China and form the subgroup for this analysis. Baseline characteristics are presented in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

“…The primary manuscript reported the efficacy, safety, and quality-of-life changes among patients who switched from a typical antipsychotic to olanzapine. 15 Data for the original study were collected from 64 investigator sites across the People’s Republic of China, Hong Kong, the Philippines, South Korea, and Taiwan. The study began in May 2002 and was completed in September 2004.…”

Section: Methodsmentioning

confidence: 99%

“…Patients met criteria for inclusion in the study if their treating physician diagnosed them with schizophrenia, according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition , 16 or the International Classification of Diseases, Tenth Revision; 17 if it was determined that their symptoms were inadequately controlled on a typical antipsychotic medication; and if they switched to the atypical antipsychotic olanzapine, at the physician’s and patient’s discretion. 15 In addition, patients were required to be between 18 and 60 years of age and to have presented during the normal course of care. Patients were excluded if they had used olanzapine (or any other atypical antipsychotic) during the 6 months before enrollment or were pregnant.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine

Montgomery

Kadziola²,

et al. 2015

NDT

View full text Add to dashboard Cite

PurposeThe aim of this study was to investigate the correlation between changes in symptoms and changes in self-reported quality of life among Chinese patients with schizophrenia who were switched from a typical antipsychotic to olanzapine during usual outpatient care.Patients and methodsThis post hoc analysis was conducted using data from the Chinese subgroup (n=475) of a multicountry, 12-month, prospective, noninterventional, observational study. The primary publication previously reported the efficacy, safety, and quality of life among patients who switched from a typical antipsychotic to olanzapine. Patients with schizophrenia were included if their symptoms were inadequately controlled with a typical antipsychotic and they were switched to olanzapine. Symptom severity was measured using the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impressions-Severity scale (CGI-S). Health-Related Quality of Life (HRQOL) was assessed using the World Health Organization Quality of Life–Abbreviated (WHOQOL-BREF). Paired t-tests were performed to assess changes from baseline to endpoint. Pearson’s correlation coefficients (r) were used to assess the correlations between change in symptoms (BPRS and CGI-S scores) and change in HRQOL (WHOQOL-BREF scores).ResultsSymptoms and HRQOL both improved significantly over the 12 months of treatment (P<0.001). Significant correlations were observed between changes from baseline to end of study on the BPRS and the CGI-S and each of the WHOQOL-BREF four domain scores and two overall quality-of-life questions. The correlation coefficients ranged from r=−0.45 to r=−0.53 for the BPRS and WHOQOL-BREF. The correlation coefficients were slightly smaller between the CGI-S and WHOQOL-BREF, ranging from r=−0.33 to r=−0.40.ConclusionFor patients with schizophrenia, assessing quality of life has the potential to add valuable information to the clinical assessment that takes into account the patient’s own perspective of well-being.

show abstract

“…Atypical antipsychotics have already become the first choice for schizophrenia treatment at different levels, at different stages and also for the prevention of recurrence. The therapeutic effects of many atypical antipsychotics have been confirmed in many clinical researches (Wang et al 2005c;Lu et al 2007;Wei et al 2006;Kuang et al 2006;Cao et al 2006). A new kind of atypical antipsychotic drug, perospirone, with the properties of both dopamine D2 receptor and serotonin receptor antagonist, has been reported to be an effective and safe drug for schizophrenia .…”

Section: Potential Therapies For Schizophreniamentioning

confidence: 93%

Recent Progress in the Research Field of Neuropharmacology in China

Jin¹

2008

Cell Mol Neurobiol

View full text Add to dashboard Cite

In recent years, Chinese neuropharmacologists have done a lot of basic and practical work in neuropharmacology, especially in the fields of pain, drug dependence, depression, Alzheimer's disease, schizophrenia, having obtained some exciting results that are of great significance for the development of neuropharmacology. Here I would like to review recent progress in the research fields of neuropharmacology in China.

show abstract

Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics

Cited by 12 publications

References 31 publications

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study

Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine

Recent Progress in the Research Field of Neuropharmacology in China

Contact Info

Product

Resources

About